Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sartorius Stedim Biotech
  6. News
  7. Summary
    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius Stedim Biotech SA : Implementation of a new contract of liquidity with Kepler Cheuvreux

05/04/2021 | 07:17am EDT
Sartorius Stedim Biotech SA 
Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux 
04-May-2021 / 13:15 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
 
Aubagne, May 4, 2021 
 
Implementation of a new contract of liquidity with Kepler Cheuvreux 
 
Sartorius Stedim Biotech and Kepler Cheuvreux have signed on April 29, 2021 a liquidity contract regarding the shares 
of Sartorius Stedim Biotech admitted to Euronext Paris (the "Agreement"). 
 
The implementation of the Agreement will be carried out in accordance with the legal provisions in force, and more 
specifically with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 
April 2014 on market abuse (MAR), the delegated Commission Regulation (EU) 2016/908 of 26 February 2016 supplementing 
Regulation (EU) No 596/2014 of the European Parliament and of the Council with regulatory technical standards 
concerning the criteria, procedure and requirements for establishing an accepted market practice and the requirements 
for maintaining, withdrawing or amending the conditions for admission, and Articles L. 225-209 et seq. of the French 
Commercial Code, and the AMF decision no. 2018-01 of July 2, 2018, applicable as of January 1, 2019. 
 
The following resources have been allocated to the liquidity account: 
  ? 10 million euros 
The execution of the Agreement will be suspended under the conditions described in Article 5 of AMF decision no. 
2018-01 of July 2, 2018. 
 
The execution of the Agreement may also be suspended: 
  ? by Sartorius Stedim Biotech, in the event that Kepler Cheuvreux has not made reasonable efforts to meet its 
    obligations with respect to the liquidity of transactions and the regularity of quotations 
  ? by Kepler Cheuvreux, when the information provided by the client makes it impossible for Kepler Cheuvreux to meet 
    its obligations; 
  ? by Kepler Cheuvreux, when the sums due to Kepler Cheuvreux under the liquidity contract have not been paid on the 
    payment date as stated in the invoice provided by Kepler Cheuvreux; and 
The Agreement may be terminated: 
  ? at any time by Sartorius Stedim Biotech, subject to two (2) business days' notice; 
  ? at any time by Kepler Cheuvreux subject to thirty (30) calendar days' notice; 
  ? without notice and without formality if the shares are transferred to another stock market. 
 
 
 
A profile of Sartorius Stedim Biotech 
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions 
provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. 
Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own 
manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, 
Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has 
been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed 
more than 7,500 people, and earned sales revenue of 1,910 million euros. 
 
Contact 
Ben Orzelek 
Head of Investor Relations 
+49 (0)551.308.1668 
Ben.orzelek@sartorius.com 
 
Sartorius Stedim Biotech S.A. 
Z.I. Les Paluds 
Avenue de Jouques, CS 91051 
13781 Aubagne Cedex, France 
Phone: +33.(0)4.42.84.56.00 
Fax: +33.(0)4.42.84.56.19 
www.sartorius-stedim.com 
 
 
=---------------------------------------------------------------------------------------------------------------------- 
Regulatory filing PDF file 
File: Implementation of a new contract of liquidity with Kepler Cheuvreux 
=------------------------------------------------------------------------------------------------------- 
Language:        English 
Company:         Sartorius Stedim Biotech SA 
                 Avenue de Jouques 
                 13781 Aubagne 
                 France 
Phone:           +33 44 284 5600 
E-mail:          info@sartorius-stedim.com 
Internet:        www.sartorius-stedim.com 
ISIN:            FR0013154002 
Euronext Ticker: DIM 
AMF Category:    Share buyback / Disposal of own shares / Information relating to the liquidity contract 
EQS News ID:     1192368 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------ 

1192368 04-May-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1192368&application_name=news 
 

(END) Dow Jones Newswires

May 04, 2021 07:16 ET (11:16 GMT)

All news about SARTORIUS STEDIM BIOTECH
05/04SARTORIUS STEDIM BIOTECH  : Implementation of a new contract of liquidity with K..
PU
05/04SARTORIUS STEDIM BIOTECH SA  : Mise en ouvre d'un nouveau contrat de liquidité a..
DJ
05/04SARTORIUS STEDIM BIOTECH SA : Implementation of a new contract of liquidity with..
EQ
05/04SARTORIUS STEDIM BIOTECH SA  : Implementation of a new contract of liquidity wit..
DJ
04/23SARTORIUS VORZUEGE  : NorldLB sticks Neutral
MD
04/23SARTORIUS VORZUEGE  : Berenberg remains Neutral
MD
04/23SARTORIUS VORZUEGE  : UBS reaffirms its Sell rating
MD
04/22SARTORIUS VORZUEGE  : JP Morgan gives a Buy rating
MD
04/21GLOBAL MARKETS LIVE : Ericsson, Netflix, Roche...
04/21SARTORIUS VORZUEGE  : JP Morgan reaffirms its Buy rating
MD
More news
Financials
Sales 2021 2 669 M 3 246 M 3 246 M
Net income 2021 493 M 600 M 600 M
Net Debt 2021 518 M 630 M 630 M
P/E ratio 2021 69,7x
Yield 2021 0,34%
Capitalization 34 521 M 41 956 M 41 987 M
EV / Sales 2021 13,1x
EV / Sales 2022 11,5x
Nbr of Employees 8 200
Free-Float 25,7%
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS STEDIM BIOTECH
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 386,89 €
Last Close Price 374,50 €
Spread / Highest target 38,9%
Spread / Average Target 3,31%
Spread / Lowest Target -31,9%
EPS Revisions
Managers and Directors
NameTitle
Joachim Kreuzburg Chairman & Chief Executive Officer
Oscar-Werner Reif Executive VP-Research & Development
Volker Niebel Executive VP-Operations & Information Technology
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH28.61%41 956
ABBOTT LABORATORIES8.49%211 353
MEDTRONIC PLC8.67%170 801
BECTON, DICKINSON AND COMPANY-4.33%69 619
ALIGN TECHNOLOGY, INC.11.97%47 351
HOYA CORPORATION-7.88%44 672